IL-18 binding proteins
View Patent ↗The present invention encompasses IL-18 binding proteins, particularly antibodies that bind human interleukin-18 (hIL-18). Specifically, the invention relates to antibodies that are entirely human antibodies. Preferred antibodies have high affinity for hIL-18 and/or that neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental.
1. An isolated binding protein capable of binding human IL-18, said binding protein comprising:
an Ig constant heavy region having the amino acid sequence selected from the group consisting of: SEQ ID NO:2, and SEQ ID NO: 3;
an Ig constant light region having the amino acid sequence selected from the group consisting of: SEQ ID NO:4, and SEQ ID NO: 5;
an Ig variable heavy region having the amino acid sequence of SEQ ID NO:6; and
an Ig variable light region having the amino acid sequence of SEQ ID NO:7.
2. An isolated binding protein capable of binding human IL-18, said binding protein comprising:
an Ig constant heavy region having the amino acid sequence of SEQ ID NO: 3;
an Ig constant light region having the amino acid sequence of SEQ ID NO:4;
an Ig variable heavy region having the amino acid sequence of SEQ ID NO:6; and
an Ig variable light region having the amino acid sequence of SEQ ID NO:7.
3. An isolated neutralizing binding protein, wherein said neutralizing binding protein comprises a binding protein according to claim 1 or 2 , and wherein said neutralizing binding protein is capable of neutralizing human IL-18.
4. The isolated neutralizing binding protein according to claim 3 , wherein said IL-18 is selected from the group consisting of pro-human IL-18, mature-human IL-18, and truncated-human IL-18.
5. The isolated neutralizing binding protein according to claim 3 , wherein said neutralizing binding protein diminishes the ability of human IL-18 to bind to its receptor.
6. The isolated neutralizing binding protein according to claim 5 , wherein said neutralizing binding protein diminishes the ability of pro-human IL-18, mature-human IL-18, or truncated-human IL-18 to bind to its receptor.
7. The isolated neutralizing binding protein according to claim 3 , wherein said neutralizing binding protein is capable of reducing one or more of human IL-18 biological activities selected from the group consisting of: Th1 modulation, Th2 modulation, NK modulation, neutrophil modulation, monocyte-macrophage lineage modulation, eosinophil modulation, B-cell modulation, cytokine modulation, chemokine modulation, adhesion molecule modulation, and cell recruitment modulation.
8. The isolated neutralizing binding protein according to claim 3 , wherein said neutralizing binding protein has a dissociation constant (K D ) selected from the group consisting of: about 10 −7 M, about 10 −8 M, about 10 −9 M, about 10 −10 M, about 10 −12 M, and about 10 −13 M.
9. The isolated neutralizing binding protein according to claim 3 , wherein said neutralizing binding protein has an on-rate selected from the group consisting of: about 10 2 M −1 s −1 , about 10 3 M −1 s −1 , about 10 4 M −1 s −1 , about 10 5 M −1 s −1 , and about 10 6 M −1 s −1 .
10. The isolated neutralizing binding protein according to claim 3 , wherein said neutralizing binding protein has an off-rate selected from the group consisting of: about 10 −3 s −1 , about 10 −4 s −1 , about 10 −5 s −1 , and about 10 −6 s −1 .
11. A labeled binding protein comprising a binding protein of claim 1 or 2 , wherein said binding protein is conjugated to a detectable label.
12. The labeled binding protein of claim 11 , wherein the detectable label is selected from the group consisting of a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, and biotin.
13. The labeled binding protein of claim 12 , wherein said label is a radiolabel selected from the group consisting of: 3 H, 14 C, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I, 177 Lu, 166 Ho, and 153 Sm.
14. A conjugate binding protein comprising a binding protein of claim 1 or 2 , wherein said binding protein is conjugated to a therapeutic or cytotoxic agent.
15. The conjugate binding protein of claim 14 , wherein said therapeutic or cytotoxic agent is selected from the group consisting of: an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, an anthracycline, toxin, and an apoptotic agent.
16. A pharmaceutical composition comprising the binding protein of claim 1 or 2 , and a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 16 , which further comprises at least one additional therapeutic agent for treating a disorder in which IL-18 activity is detrimental.
18. The pharmaceutical composition of claim 17 , wherein said additional agent is selected from the group consisting of: angiogenesis inhibitors; kinase inhibitors; co-stimulation molecule blockers; adhesion molecule blockers; anti-cytokine antibody or functional fragment thereof; methotrexate; corticosteroids; cyclosporin; rapamycin; FK506; and non-steroidal anti-inflammatory agents.
19. An isolated nucleic acid encoding the binding protein according to claim 1 or 2 .
20. A vector comprising the isolated nucleic acid according to claim 19 .
21. The vector of claim 20 wherein said vector is selected from the group consisting of pcDNA, pTT, pTT3, pEFBOS, pBV, pJV, and pBJ.
22. An isolated host cell comprising a vector according to claim 20 .
23. The host cell according to claim 22 , wherein said host cell is a prokaryotic cell.
24. The host cell according to claim 23 , wherein said host cell is E. coli.
25. The host cell according to claim 22 , wherein said host cell is an eukaryotic cell.
26. The host cell according to claim 25 , wherein said eukaryotic cell is selected from the group consisting of animal cell, plant cell, and fungal cell.
27. The host cell according to claim 26 , wherein said eukaryotic cell is an animal cell selected from the group consisting of a mammalian cell, an avian cell, and an insect cell.
28. The host cell according to claim 27 , wherein said animal cell is a CHO cell.
29. The host cell according to claim 27 , wherein said host cell is COS.
30. The host cell according to claim 26 , wherein said eukaryotic cell is Saccharomyces cerevisiae.
31. The host cell according to claim 27 , wherein said animal cell is an insect Sf9 cell.
32. A method of producing a binding protein that binds human IL-18, comprising culturing the host cell of claim 22 in a culture medium under conditions sufficient to produce a binding protein that binds human IL-18.
33. An isolated binding protein comprising an antigen binding domain capable of binding human IL-18, wherein said antigen binding domain comprises a CDR-H1 having Residues 31-35 of SEQ ID NO.:6; a CDR-H2 having Residues 50-66 of SEQ ID NO.:6; a CDR-H3 having Residues 99-110 of SEQ ID NO.:6; a CDR-L1 having Residues 24-34 of SEQ ID NO.:7; a CDR-L2 having Residues 50-56 of SEQ ID NO.:7; and a CDR-L3 having Residues 89-98 of SEQ ID NO.:7.
34. The isolated binding protein according to claim 33 , wherein said antigen binding domain comprises a V H .
35. The isolated binding protein according to claim 34 , wherein said V H comprises the amino acid sequence of SEQ ID NO: 6.
36. The isolated binding protein according to claim 33 , wherein said antigen binding domain comprises a V L .
37. The isolated binding protein according to claim 36 , wherein said V L comprises the amino acid sequence of SEQ ID NO: 7.
38. The isolated binding protein according to claim 33 , wherein said antigen binding domain comprises a V H and a V L .
39. The isolated binding protein according to claim 38 , wherein said V L comprises the amino acid sequence of SEQ ID NO: 7, and said V H comprises the amino acid sequence of SEQ ID NO: 6.
40. The isolated binding protein according to claim 33 , further comprising a heavy chain immunoglobulin constant domain selected from the group consisting of: a human IgM constant domain; a human IgG1 constant domain; a human IgG2 constant domain; a human IgG3 constant domain; a human IgG4 constant domain; a human IgE constant domain and a human IgA constant domain.
41. The isolated binding protein according to claim 40 , wherein said heavy chain immunoglobulin constant domain is a human IgG1 constant domain.
42. The isolated binding protein according to claim 41 , wherein said human IgG1 constant domain comprises the amino acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:3.
43. The isolated binding protein according to claim 33 , further comprising a light chain immunoglobulin constant domain selected from the group consisting of: a human Ig kappa constant domain; and a human Ig lambda constant domain.
44. The isolated binding protein according to claim 43 , wherein said light chain immunoglobulin constant domain is a human Ig kappa constant domain comprising the amino acid sequence of SEQ ID NO.: 4.
45. The isolated binding protein according to claim 43 , wherein said light chain immunoglobulin constant domain is a human Ig lambda constant domain comprising the amino acid sequence of SEQ ID NO.: 5.
46. The isolated binding protein according to claim 33 , wherein said binding protein is selected from the group consisting of: an immunoglobulin molecule; an scFv; a monoclonal antibody; a human antibody; a chimeric antibody; a humanized antibody; a Fab fragment; an Fab′ fragment; an F(ab′) 2 ; an Fv; and a disulfide linked Fv.
47. The isolated binding protein according to claim 46 , wherein said binding protein is a human antibody.
48. The isolated binding protein according to claim 33 , wherein said binding protein binds human IL-18 but is not capable of competing with a binding protein selected from the group consisting of 2.5(E)mg1 antibody and IL-18BP for binding human IL-18.
49. An isolated neutralizing binding protein, wherein said neutralizing binding protein comprises a binding protein according to any one of claims 33 - 47 , and wherein said neutralizing binding protein is capable of neutralizing human IL-18.
50. The isolated neutralizing binding protein according to claim 49 , wherein said IL-18 is selected from the group consisting of pro-human IL-18, mature-human IL-18, and truncated-human IL-18.
51. The isolated neutralizing binding protein according to claim 49 , wherein said neutralizing binding protein diminishes the ability of human IL-18 to bind to its receptor.
52. The isolated neutralizing binding protein according to claim 51 , wherein said neutralizing binding protein diminishes the ability of pro-human IL-18, mature-human IL-18, or truncated-human IL-18 to bind to its receptor.
53. The isolated neutralizing binding protein according to claim 49 , wherein said neutralizing binding protein is capable of reducing one or more of human IL-18 biological activities selected from the group consisting of: Th1 modulation, Th2 modulation, NK modulation, neutrophil modulation, monocyte-macrophage lineage modulation, eosinophil modulation, B-cell modulation, cytokine modulation, chemokine modulation, adhesion molecule modulation, and cell recruitment modulation.
54. The isolated neutralizing binding protein according to claim 49 , wherein said neutralizing binding protein has a dissociation constant (K D ) selected from the group consisting of: about 10 −7 M; about 10 −8 M; about 10 −9 M; about 10 −10 M; about 10 −11 M; about 10 −12 M; and about 10 −13 M.
55. The isolated neutralizing binding protein according to claim 49 , wherein said neutralizing binding protein has an on-rate selected from the group consisting of: about 10 2 M −1 s −1 , about 10 3 M −1 s −1 , about 10 4 M −1 s −1 , about 10 5 M −1 s −1 , and about 10 6 M −1 s −1 .
56. The isolated neutralizing binding protein according to claim 49 , wherein said neutralizing binding protein has an off-rate selected from the group consisting of: about 10 −3 s −1 , about 10 −4 s −1 , about 10 5 s −1 , and about 10 −6 s −1 .
57. A labeled binding protein comprising a binding protein of any one of claims 33 - 47 , wherein said binding protein is conjugated to a detectable label.
58. The labeled binding protein of claim 57 , wherein the detectable label is selected from the group consisting of a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, and biotin.
59. The labeled binding protein of claim 58 , wherein said label is a , radiolabel selected from the group consisting of: 3 H, 14 C, 35 S, 90 Y, 99 C, 111 In, 125 I, 131 I, 177 Lu, 166 Ho, and 153 Sm.
60. A conjugate binding protein comprising a binding protein of any one of claims 33 - 47 , wherein said binding protein is conjugated to a therapeutic or cytotoxic agent.
61. The conjugate binding protein of claim 60 , wherein said therapeutic or cytotoxic agent is selected from the group consisting of: an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, an anthracycline, toxin, and an apoptotic agent.
62. A pharmaceutical composition comprising the binding protein of any one of claims 33 - 47 , and a pharmaceutically acceptable carrier.
63. The pharmaceutical composition of claim 62 , which further comprises at least one additional therapeutic agent for treating a disorder in which IL-18 activity is detrimental.
64. The pharmaceutical composition of claim 63 , wherein said additional agent is selected from the group consisting of: angiogenesis inhibitors; kinase inhibitors; co-stimulation molecule blockers; adhesion molecule blockers; anti-cytokine antibody or functional fragment thereof; methotrexate; corticosteroids; cyclosporin; rapamycin; FK506; and non-steroidal anti-inflammatory agents.